Alterity Net Receivables vs Total Liab Analysis

ATHE Stock

USD 1.87 0.01 0.53%

Alterity Therapeutics financial indicator trend analysis is way more than just evaluating Alterity Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alterity Therapeutics is a good investment. Please check the relationship between Alterity Therapeutics Net Receivables and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.

Net Receivables vs Total Liab

Net Receivables vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alterity Therapeutics Net Receivables account and Total Liab. At this time, the significance of the direction appears to have strong relationship.

The correlation between Alterity Therapeutics' Net Receivables and Total Liab is 0.61. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Total Liab in the same time period over historical financial statements of Alterity Therapeutics, assuming nothing else is changed. The correlation between historical values of Alterity Therapeutics' Net Receivables and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Alterity Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Net Receivables i.e., Alterity Therapeutics' Net Receivables and Total Liab go up and down completely randomly.

Correlation Coefficient

0.61

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Receivables

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Alterity Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alterity Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.At present, Alterity Therapeutics' Enterprise Value is projected to increase significantly based on the last few years of reporting.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	54.2K	102.3K	92.0K	87.4K
Research Development	14.7M	13.2M	15.2M	7.7M

Depreciation And Amortization Research Development

Alterity Therapeutics fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Current Assets	Common Stock	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Inventory	Other Current Assets	Total Liab	Intangible Assets	Common Stock Total Equity	Non Current Liabilities Total	Property Plant And Equipment Gross	Short Long Term Debt Total	Current Deferred Revenue
Total Assets		1.0	-0.95	0.97	0.97	0.25	-0.68	1.0	0.58	0.22	0.64	0.09	-0.56	0.47	-0.54	-0.37	0.57	0.21	0.15	0.63	-0.26	0.68	0.22	0.21	-0.41	0.18
Total Stockholder Equity	1.0		-0.96	0.98	0.98	0.2	-0.71	0.99	0.54	0.22	0.57	0.04	-0.51	0.42	-0.51	-0.31	0.54	0.16	0.18	0.56	-0.28	0.63	0.16	0.16	-0.43	0.13
Net Debt	-0.95	-0.96		-1.0	-1.0	-0.02	0.85	-0.95	-0.39	-0.02	-0.45	0.14	0.39	-0.36	0.48	0.17	-0.33	0.04	-0.18	-0.44	0.33	-0.5	0.04	0.01	0.45	0.04
Cash	0.97	0.98	-1.0		1.0	0.08	-0.81	0.97	0.44	0.07	0.5	-0.08	-0.42	0.38	-0.49	-0.22	0.39	0.02	0.18	0.49	-0.32	0.54	0.02	0.04	-0.43	0.01
Cash And Short Term Investments	0.97	0.98	-1.0	1.0		0.08	-0.81	0.97	0.44	0.07	0.5	-0.08	-0.42	0.38	-0.49	-0.22	0.39	0.02	0.18	0.48	-0.32	0.54	0.02	0.04	-0.43	0.01
Common Stock Shares Outstanding	0.25	0.2	-0.02	0.08	0.08		0.4	0.21	0.74	0.44	0.64	0.96	-0.63	0.42	-0.14	-0.84	0.74	0.94	-0.24	0.66	0.37	0.48	0.87	1.0	0.06	0.99
Other Stockholder Equity	-0.68	-0.71	0.85	-0.81	-0.81	0.4		-0.7	-0.01	0.38	-0.15	0.5	0.06	-0.27	0.25	-0.19	0.13	0.44	-0.08	-0.13	0.31	-0.22	0.39	0.41	0.54	0.43
Total Current Assets	1.0	0.99	-0.95	0.97	0.97	0.21	-0.7		0.55	0.19	0.64	0.05	-0.54	0.46	-0.53	-0.35	0.53	0.17	0.15	0.63	-0.26	0.68	0.2	0.17	-0.41	0.14
Common Stock	0.58	0.54	-0.39	0.44	0.44	0.74	-0.01	0.55		0.59	0.68	0.63	-0.95	0.43	-0.65	-0.77	0.83	0.82	-0.37	0.7	-0.01	0.85	0.76	0.71	-0.31	0.66
Other Current Liab	0.22	0.22	-0.02	0.07	0.07	0.44	0.38	0.19	0.59		0.15	0.41	-0.47	-0.18	-0.4	-0.4	0.74	0.57	0.1	0.16	-0.21	0.38	0.42	0.4	0.03	0.37
Total Current Liabilities	0.64	0.57	-0.45	0.5	0.5	0.64	-0.15	0.64	0.68	0.15		0.51	-0.73	0.74	-0.44	-0.78	0.6	0.57	-0.16	1.0	0.1	0.77	0.69	0.62	-0.02	0.56
Property Plant And Equipment Net	0.09	0.04	0.14	-0.08	-0.08	0.96	0.5	0.05	0.63	0.41	0.51		-0.51	0.41	0.07	-0.8	0.67	0.94	-0.26	0.53	0.56	0.35	0.86	0.97	0.09	0.96
Retained Earnings	-0.56	-0.51	0.39	-0.42	-0.42	-0.63	0.06	-0.54	-0.95	-0.47	-0.73	-0.51		-0.41	0.72	0.74	-0.68	-0.72	0.45	-0.73	0.01	-0.92	-0.76	-0.6	0.29	-0.54
Accounts Payable	0.47	0.42	-0.36	0.38	0.38	0.42	-0.27	0.46	0.43	-0.18	0.74	0.41	-0.41		-0.1	-0.55	0.46	0.38	-0.23	0.74	0.22	0.44	0.46	0.43	-0.27	0.41
Non Current Assets Total	-0.54	-0.51	0.48	-0.49	-0.49	-0.14	0.25	-0.53	-0.65	-0.4	-0.44	0.07	0.72	-0.1		0.26	-0.45	-0.2	0.08	-0.44	0.66	-0.7	-0.2	-0.07	0.19	-0.03
Non Currrent Assets Other	-0.37	-0.31	0.17	-0.22	-0.22	-0.84	-0.19	-0.35	-0.77	-0.4	-0.78	-0.8	0.74	-0.55	0.26		-0.67	-0.83	0.33	-0.79	-0.35	-0.61	-0.82	-0.83	-0.13	-0.76
Net Receivables	0.57	0.54	-0.33	0.39	0.39	0.74	0.13	0.53	0.83	0.74	0.6	0.67	-0.68	0.46	-0.45	-0.67		0.78	0.05	0.61	-0.05	0.6	0.67	0.71	-0.17	0.68
Inventory	0.21	0.16	0.04	0.02	0.02	0.94	0.44	0.17	0.82	0.57	0.57	0.94	-0.72	0.38	-0.2	-0.83	0.78		-0.37	0.59	0.39	0.57	0.92	0.94	-0.03	0.92
Other Current Assets	0.15	0.18	-0.18	0.18	0.18	-0.24	-0.08	0.15	-0.37	0.1	-0.16	-0.26	0.45	-0.23	0.08	0.33	0.05	-0.37		-0.17	-0.3	-0.37	-0.38	-0.25	0.37	-0.25
Total Liab	0.63	0.56	-0.44	0.49	0.48	0.66	-0.13	0.63	0.7	0.16	1.0	0.53	-0.73	0.74	-0.44	-0.79	0.61	0.59	-0.17		0.12	0.77	0.71	0.64	-0.02	0.58
Intangible Assets	-0.26	-0.28	0.33	-0.32	-0.32	0.37	0.31	-0.26	-0.01	-0.21	0.1	0.56	0.01	0.22	0.66	-0.35	-0.05	0.39	-0.3	0.12		-0.06	0.48	0.44	0.09	0.44
Common Stock Total Equity	0.68	0.63	-0.5	0.54	0.54	0.48	-0.22	0.68	0.85	0.38	0.77	0.35	-0.92	0.44	-0.7	-0.61	0.6	0.57	-0.37	0.77	-0.06		0.67	0.44	-0.36	0.4
Non Current Liabilities Total	0.22	0.16	0.04	0.02	0.02	0.87	0.39	0.2	0.76	0.42	0.69	0.86	-0.76	0.46	-0.2	-0.82	0.67	0.92	-0.38	0.71	0.48	0.67		0.87	-0.02	0.84
Property Plant And Equipment Gross	0.21	0.16	0.01	0.04	0.04	1.0	0.41	0.17	0.71	0.4	0.62	0.97	-0.6	0.43	-0.07	-0.83	0.71	0.94	-0.25	0.64	0.44	0.44	0.87		0.07	0.99
Short Long Term Debt Total	-0.41	-0.43	0.45	-0.43	-0.43	0.06	0.54	-0.41	-0.31	0.03	-0.02	0.09	0.29	-0.27	0.19	-0.13	-0.17	-0.03	0.37	-0.02	0.09	-0.36	-0.02	0.07		0.01
Current Deferred Revenue	0.18	0.13	0.04	0.01	0.01	0.99	0.43	0.14	0.66	0.37	0.56	0.96	-0.54	0.41	-0.03	-0.76	0.68	0.92	-0.25	0.58	0.44	0.4	0.84	0.99	0.01

Click cells to compare fundamentals

Alterity Therapeutics Account Relationship Matchups

Alterity Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	13.3M	33.6M	41.4M	27.3M	31.4M	21.8M
Total Stockholder Equity	10.5M	30.5M	35.5M	22.8M	26.2M	19.3M
Net Debt	(9.2M)	(28.0M)	(34.7M)	(15.6M)	(14.0M)	(14.7M)
Cash	9.2M	28.1M	34.8M	15.8M	18.1M	15.8M
Cash And Short Term Investments	9.2M	28.1M	34.8M	15.8M	18.1M	15.8M
Common Stock Shares Outstanding	1.5M	2.8M	2.4B	2.4B	2.8B	2.9B
Liabilities And Stockholders Equity	13.3M	33.6M	41.4M	27.3M	31.4M	21.8M
Other Stockholder Equity	(4.3M)	(20.8M)	(22.0M)	4.0M	3.6M	3.4M
Total Current Assets	13.2M	33.5M	41.1M	27.0M	31.1M	18.6M
Common Stock	160.7M	197.4M	213.8M	214.0M	246.1M	258.4M
Other Current Liab	1.2M	1.2M	(26.9K)	2.6M	2.9M	3.1M
Total Current Liabilities	2.7M	3.1M	5.8M	4.4M	5.0M	2.7M
Property Plant And Equipment Net	71.4K	96.8K	218.5K	268.9K	309.2K	324.7K
Retained Earnings	(151.0M)	(169.7M)	(181.9M)	(195.1M)	(175.6M)	(166.8M)
Accounts Payable	954.0K	1.4M	2.7M	1.7M	2.0M	1.3M
Non Current Assets Total	71.4K	96.8K	218.5K	268.9K	242.0K	229.9K
Non Currrent Assets Other	(34.2K)	(49.3K)	(72.6K)	(150.9K)	(135.8K)	(129.0K)
Net Receivables	3.5M	4.3M	4.7M	8.7M	10.0M	10.5M
Inventory	567.9K	1.1M	1.6M	2.6M	3.0M	3.1M
Other Current Assets	10.3K	9.4K	10.2K	39.8K	35.8K	34.0K
Total Liab	2.8M	3.1M	5.9M	4.5M	5.2M	2.8M
Common Stock Total Equity	143.9M	156.6M	160.7M	197.4M	227.1M	128.1M
Non Current Liabilities Total	42.4K	47.7K	73.6K	122.7K	110.4K	69.6K
Property Plant And Equipment Gross	71.4K	96.8K	733.1K	728.8K	838.1K	880.0K
Accumulated Other Comprehensive Income	866.1K	2.8M	3.6M	4.0M	4.6M	4.8M
Short Long Term Debt Total	33.7K	65.6K	117.5K	210.4K	189.3K	132.0K
Short Term Debt	32.9K	27.7K	57.6K	107.2K	96.5K	107.5K
Other Assets	(0.53)	0.03	(0.48)	1.0	0.9	0.86
Other Liab	41.5K	9.8K	13.8K	19.5K	22.4K	15.0K
Net Tangible Assets	7.2M	30.5M	35.5M	22.8M	26.2M	24.6M
Capital Lease Obligations	33.7K	65.6K	117.5K	210.4K	241.9K	254.0K
Property Plant Equipment	71.4K	96.8K	218.5K	268.9K	309.2K	324.7K
Net Invested Capital	7.2M	30.5M	35.5M	22.8M	26.2M	23.9M
Net Working Capital	7.1M	30.4M	35.3M	22.7M	26.1M	23.8M
Capital Stock	160.7M	197.4M	213.8M	214.0M	246.1M	207.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports:

How To Invest In Alterity

Details

Is Alterity Stock a good investment?

Details

What is Alterity Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.

Note that the Alterity Therapeutics information on this page should be used as a complementary analysis to other Alterity Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Alterity Stock analysis

When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	CEOs Directory Screen CEOs from public companies around the world

Is Alterity Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.75)

Revenue Per Share

0.6

Quarterly Revenue Growth

(0.20)

Return On Assets

(0.29)

Return On Equity

(0.54)

The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alterity Net Receivables vs Total Liab Analysis

Net Receivables vs Total Liab

Net Receivables vs Total Liab Correlation Analysis

Correlation Coefficient

Net Receivables

Total Liab

Alterity Therapeutics fundamental ratios Correlations

Alterity Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alterity Therapeutics fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Alterity Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Gross	+ 1.0	Common Stock Shares Outstanding
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 0.99	Total Stockholder Equity

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 0.96	Total Stockholder Equity
Retained Earnings	- 0.95	Common Stock
Total Current Assets	- 0.95	Net Debt
Net Debt	- 0.95	Total Assets